Validated Prognostic Nomograms for Patients With Parotid Carcinoma Predicting 2- and 5-Year Tumor Recurrence-Free Interval Probability
Introduction: Salivary gland malignancies are rare tumors with a heterogenous histological and clinical appearance. Previously, we identified multiple prognostic factors in patients with parotid cancer and developed prognostic indices which have repeatedly been validated internationally, demonstrati...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.01535/full |
id |
doaj-2ece99e2254c47c9a3fb24765603ee1f |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sam Peeperkorn Sam Peeperkorn Jeroen Meulemans Jeroen Meulemans Charlotte Van Lierde Charlotte Van Lierde Annouschka Laenen Matthijs H. Valstar Matthijs H. Valstar A. J. M. Balm A. J. M. Balm Pierre Delaere Pierre Delaere Vincent Vander Poorten Vincent Vander Poorten |
spellingShingle |
Sam Peeperkorn Sam Peeperkorn Jeroen Meulemans Jeroen Meulemans Charlotte Van Lierde Charlotte Van Lierde Annouschka Laenen Matthijs H. Valstar Matthijs H. Valstar A. J. M. Balm A. J. M. Balm Pierre Delaere Pierre Delaere Vincent Vander Poorten Vincent Vander Poorten Validated Prognostic Nomograms for Patients With Parotid Carcinoma Predicting 2- and 5-Year Tumor Recurrence-Free Interval Probability Frontiers in Oncology oncological outcome nomograms parotid carcinoma prognosis tumor recurrence-free interval |
author_facet |
Sam Peeperkorn Sam Peeperkorn Jeroen Meulemans Jeroen Meulemans Charlotte Van Lierde Charlotte Van Lierde Annouschka Laenen Matthijs H. Valstar Matthijs H. Valstar A. J. M. Balm A. J. M. Balm Pierre Delaere Pierre Delaere Vincent Vander Poorten Vincent Vander Poorten |
author_sort |
Sam Peeperkorn |
title |
Validated Prognostic Nomograms for Patients With Parotid Carcinoma Predicting 2- and 5-Year Tumor Recurrence-Free Interval Probability |
title_short |
Validated Prognostic Nomograms for Patients With Parotid Carcinoma Predicting 2- and 5-Year Tumor Recurrence-Free Interval Probability |
title_full |
Validated Prognostic Nomograms for Patients With Parotid Carcinoma Predicting 2- and 5-Year Tumor Recurrence-Free Interval Probability |
title_fullStr |
Validated Prognostic Nomograms for Patients With Parotid Carcinoma Predicting 2- and 5-Year Tumor Recurrence-Free Interval Probability |
title_full_unstemmed |
Validated Prognostic Nomograms for Patients With Parotid Carcinoma Predicting 2- and 5-Year Tumor Recurrence-Free Interval Probability |
title_sort |
validated prognostic nomograms for patients with parotid carcinoma predicting 2- and 5-year tumor recurrence-free interval probability |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2020-08-01 |
description |
Introduction: Salivary gland malignancies are rare tumors with a heterogenous histological and clinical appearance. Previously, we identified multiple prognostic factors in patients with parotid cancer and developed prognostic indices which have repeatedly been validated internationally, demonstrating their general applicability and lasting relevance. Recently, nomograms gained popularity as a prognostic tool. Thus, in this research we aimed to construct nomograms based on our previous validated prognostic models.Material and Methods: Nomograms were constructed using the previously reported dataset of 168 patients with parotid cancer which was used to develop pre- and postoperative prognostic scores, PS1 and PS2, respectively. Concordance indices for PS1 and PS2 were previously estimated at 0.74 and 0.71, respectively, and are in line with other, widely accepted oncological nomograms.Results: Pre- and postoperative nomograms predicting 2- and 5-year tumor recurrence-free survival probability are presented. All previously multivariately identified and validated prognostic factors, are incorporated (T size, N classification, pain, age at diagnosis, skin invasion, facial nerve dysfunction, perineural growth, and positive surgical margins). Examples of clinical application and interpretation are given.Conclusions: The presented prognostic nomograms for predicting 2- and 5-year tumor recurrence-free probability in patients with parotid cancer are powerful, user-friendly, visual tools and are based on internationally validated prognostic indices. They allow for a reliable prognostic assessment and result in a more individualized estimate of the risk for recurrence than the prognostic grouping based on PS1 and PS2. This facilitates assigning trial-patients to risk groups, and may assist in therapeutic decision making and determining appropriate follow-up intervals in clinical practice. |
topic |
oncological outcome nomograms parotid carcinoma prognosis tumor recurrence-free interval |
url |
https://www.frontiersin.org/article/10.3389/fonc.2020.01535/full |
work_keys_str_mv |
AT sampeeperkorn validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT sampeeperkorn validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT jeroenmeulemans validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT jeroenmeulemans validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT charlottevanlierde validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT charlottevanlierde validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT annouschkalaenen validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT matthijshvalstar validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT matthijshvalstar validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT ajmbalm validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT ajmbalm validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT pierredelaere validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT pierredelaere validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT vincentvanderpoorten validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability AT vincentvanderpoorten validatedprognosticnomogramsforpatientswithparotidcarcinomapredicting2and5yeartumorrecurrencefreeintervalprobability |
_version_ |
1724488078826930176 |
spelling |
doaj-2ece99e2254c47c9a3fb24765603ee1f2020-11-25T03:51:24ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-08-011010.3389/fonc.2020.01535566264Validated Prognostic Nomograms for Patients With Parotid Carcinoma Predicting 2- and 5-Year Tumor Recurrence-Free Interval ProbabilitySam Peeperkorn0Sam Peeperkorn1Jeroen Meulemans2Jeroen Meulemans3Charlotte Van Lierde4Charlotte Van Lierde5Annouschka Laenen6Matthijs H. Valstar7Matthijs H. Valstar8A. J. M. Balm9A. J. M. Balm10Pierre Delaere11Pierre Delaere12Vincent Vander Poorten13Vincent Vander Poorten14Otorhinolaryngology - Head and Neck Surgery, Leuven Cancer Institute, University Hospitals Leuven, Leuven, BelgiumSection Head and Neck Oncology, Department of Oncology, KU Leuven, Leuven, BelgiumOtorhinolaryngology - Head and Neck Surgery, Leuven Cancer Institute, University Hospitals Leuven, Leuven, BelgiumSection Head and Neck Oncology, Department of Oncology, KU Leuven, Leuven, BelgiumOtorhinolaryngology - Head and Neck Surgery, Leuven Cancer Institute, University Hospitals Leuven, Leuven, BelgiumSection Head and Neck Oncology, Department of Oncology, KU Leuven, Leuven, BelgiumKU Leuven Department of Public Health and Primary Care, Leuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat), Leuven, BelgiumHead and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, NetherlandsDepartment of Oral and Maxillofacial Surgery, Amsterdam University Medical Center, Amsterdam, NetherlandsHead and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, NetherlandsDepartment of Oral and Maxillofacial Surgery, Amsterdam University Medical Center, Amsterdam, NetherlandsOtorhinolaryngology - Head and Neck Surgery, Leuven Cancer Institute, University Hospitals Leuven, Leuven, BelgiumSection Head and Neck Oncology, Department of Oncology, KU Leuven, Leuven, BelgiumOtorhinolaryngology - Head and Neck Surgery, Leuven Cancer Institute, University Hospitals Leuven, Leuven, BelgiumSection Head and Neck Oncology, Department of Oncology, KU Leuven, Leuven, BelgiumIntroduction: Salivary gland malignancies are rare tumors with a heterogenous histological and clinical appearance. Previously, we identified multiple prognostic factors in patients with parotid cancer and developed prognostic indices which have repeatedly been validated internationally, demonstrating their general applicability and lasting relevance. Recently, nomograms gained popularity as a prognostic tool. Thus, in this research we aimed to construct nomograms based on our previous validated prognostic models.Material and Methods: Nomograms were constructed using the previously reported dataset of 168 patients with parotid cancer which was used to develop pre- and postoperative prognostic scores, PS1 and PS2, respectively. Concordance indices for PS1 and PS2 were previously estimated at 0.74 and 0.71, respectively, and are in line with other, widely accepted oncological nomograms.Results: Pre- and postoperative nomograms predicting 2- and 5-year tumor recurrence-free survival probability are presented. All previously multivariately identified and validated prognostic factors, are incorporated (T size, N classification, pain, age at diagnosis, skin invasion, facial nerve dysfunction, perineural growth, and positive surgical margins). Examples of clinical application and interpretation are given.Conclusions: The presented prognostic nomograms for predicting 2- and 5-year tumor recurrence-free probability in patients with parotid cancer are powerful, user-friendly, visual tools and are based on internationally validated prognostic indices. They allow for a reliable prognostic assessment and result in a more individualized estimate of the risk for recurrence than the prognostic grouping based on PS1 and PS2. This facilitates assigning trial-patients to risk groups, and may assist in therapeutic decision making and determining appropriate follow-up intervals in clinical practice.https://www.frontiersin.org/article/10.3389/fonc.2020.01535/fulloncological outcomenomogramsparotid carcinomaprognosistumor recurrence-free interval |